FDA Workshop: 7th Annual Clinical Outcome Assessment in Cancer Clinical Trials Workshop

The overarching aim of this year’s workshop is to provide a forum for discussions to advance the understanding of the complex regulatory, health care policy, and scientific issues surrounding the use of patient-reported outcome (PRO) measures in cancer clinical trials.

The workshop will be open to the public, fully virtual, and will include an extremely knowledgeable and diverse group of panelists. During the three sessions of this workshop, we will focus our discussions on regulatory-grade patient-generated data and consider how collection of PROs can be affected by patients knowledge of their treatment while participating in cancer trials.

When & Where
Location: Virtual
June 29, 2022 |8:00am - 1:00pm MT

FDA Workshop: 7th Annual Clinical Outcome Assessment in Cancer Clinical Trials Workshop

The overarching aim of this year’s workshop is to provide a forum for discussions to advance the understanding of the complex regulatory, health care policy, and scientific issues surrounding the use of patient-reported outcome (PRO) measures in cancer clinical trials.

The workshop will be open to the public, fully virtual, and will include an extremely knowledgeable and diverse group of panelists. During the three sessions of this workshop, we will focus our discussions on regulatory-grade patient-generated data and consider how collection of PROs can be affected by patients knowledge of their treatment while participating in cancer trials.

When & Where
Location: Virtual
June 29, 2022 |8:00am - 1:00pm MT